3rd Annual Peptide-Based Therapeutics Summit

3rd Annual Peptide-Based Therapeutics Summit is organized by Hanson Wade and will be held from Apr 28 - 30, 2026 at Hilton Boston Logan Airport, Boston, Massachusetts, United States of America.

Description:
Peptide therapies are rapidly becoming a disruptive modality, led by Merck’s oral PCSK9 inhibitor and Johnson and Johnson’s IL23R, with the hope to develop best-in-class drugs with improved chemistry, formulation and clinical efficacy.

To shine a light on the progress of this field, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments.

Gathering industry leaders including Parabilis Medicines, Circle Pharma, Abbvie, Merck, Chugai Pharmaceuticals and many more, this is your premium forum to explore:

• Novel computational tools
• Optimize analytical assays
• Formulating cell-specific delivery methods
• DMPK translatability towards clinical success of peptide therapies

Join 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R AND D, medicinal chemistry, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization.

Speakers: Pete Gough, Head of Research, Nimble Therapeutics, Shelley Allen, Project Director II, Immuno-Pharmacology and Peptide Discovery, Abbvie, Annette Bak, Head of Advanced Drug Delivery, AstraZeneca, Atsushi Matsuo, Research Scientist, Chugai Pharmaceuticals, Byungkook Qook Lee, Research and Development Scientist (Research Advisor), Eli Lilly, Sumit Arora, Senior Principal Scientist, Oral Peptides, Johnson and Johnson, Maria Fawaz, Associate Principal Scientist, DMPK, Merck and Co, Kaustav Biswas, Senior Principal Scientist, Boston Discovery Chemistry, Merck and Co, Wen Jianzhong, Senior Principal Scientist and Group Lead, Merck and Co, Chen Liang, Senior Scientist II, Novo Nordisk, Olivera Grubisha, Senior Group Leader, In Vitro Pharmacology, UCB, Phil Brandish, Chief Scientific Officer, AI Proteins, Christopher Brown, Principal Investigator, Agency for Science, Technology and Research (A*STAR), Ajay Kshatriya, Chief Executive Officer, Aizen Therapeutics, Breena Fraga-Walton, Senior Scientist, Circle Pharma, Florian Föger, Chief Executive Officer, Cyprumed, David Earp, President and Chief Executive Officer, Circle Pharma, Gilles Divita, Chief Executive Officer, Divincell, Michael Lipp, Chief Technology Officer, Decoy Therapeutics, Barbara Hibner, Chief Scientific Officer, Decoy Therapeutics, Charles Johannes, Founder, President and Chief Scientist, EPOC Scientific, Soultan Al-Halifa, Director R AND D, Biopharmaceutical Chemistry, Feldan Therapeutics, Hideki Tomioka, Chief Scientific Officer, Member of the Board, Director of Research and Development, FunPep, Bradley Pentelute, Professor of Chemistry, MIT, Tomi Sawyer, Chief Drug Hunter and President, Maestro Therapeutics, Kevin McDonnell, Senior Vice President, Chemistry and Discovery, Newco, Justin Lawrie, Senior Scientist, Parabilis Medicines, Immanuel Lerner, Founder and Chief Executive Officer, Pepticom, Ved Srivastava, Chief Technology Officer, Perpetual Medicines, David White, Senior Vice President, Head of Drug Discovery, ProteinQure, Sam Hong, Senior Director, Head of Platform, Rapafusyn Pharmaceuticals, Barry Kappel, Founder, President and Chief Executive Officer, Sapience Therapeutics, David Brayden, Professor of Advanced Drug Delivery, University College Dublin, Cameron Pye, Chief Executive Officer, Unnatural Products, Joshua Schwochert, Chief Scientific Officer, Unnatural Products, Thomas von Erlach, Co-Founder and Chief Scientific Officer, Vivtex, Peter Knauer, Distinguished Fellow, CMC, Xeris Biopharma, Antoine Henninot, Senior Director, Drug Maker and Peptide Chemistry, Curie.Bio, Mi Cai, Patent Attorney, Foley Hoag, Kevin Carrick, Senior Director Global Biologics, US Pharmacopoeia, Julie Zhang, Team Lead, Principal Scientist, Global Biologics, US Pharmacopoeia, Alex Loftis, Principal, Vida Ventures